Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.